Author: Harish Patel
Abstract: Neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, and Huntington's disease present significant therapeutic challenges due to the blood-brain barrier (BBB) and the need for targeted drug delivery systems. Lipid-based nanocarriers (LBNs), such as liposomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), have gained substantial interest in recent years as effective drug delivery systems for NDs. These nanocarriers offer various advantages, including enhanced bioavailability, improved solubility, controlled release, and the ability to cross the BBB. This paper explores the pharmaceutical applications of lipid-based nanocarriers in the treatment of neurodegenerative diseases, focusing on their design, mechanisms of action, and efficacy in preclinical and clinical studies.
Keywords: Lipid-based nanocarriers, Neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Blood-brain barrier, Liposomes, Solid lipid nanoparticles, Nanostructured lipid carriers, Drug delivery systems.
Full Issue
| View or download the full issue | PDF 75-85 |